The EMPULSE and SOLOIST-WHF trials explored the benefits of using SGLT2 inhibitors in AHF; however, both trials excluded patients whose HF was preceded by an ACS event 3 months prior to enrollment (15, 16). The gene discussed is SLC5A2; the disease is hydrops fetalis.